Solid Biosciences (SLDB) Operating Income (2017 - 2024)
Solid Biosciences (SLDB) has disclosed Operating Income for 8 consecutive years, with -$39.9 million as the latest value for Q4 2024.
- Quarterly Operating Income fell 79.19% to -$39.9 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$129.7 million through Dec 2024, down 24.44% year-over-year, with the annual reading at -$179.2 million for FY2025, 38.14% down from the prior year.
- Operating Income hit -$39.9 million in Q4 2024 for Solid Biosciences, down from -$35.2 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$16.9 million in Q1 2021 to a low of -$39.9 million in Q4 2024.
- Historically, Operating Income has averaged -$25.1 million across 5 years, with a median of -$24.2 million in 2022.
- Biggest five-year swings in Operating Income: surged 37.13% in 2021 and later plummeted 85.32% in 2022.
- Year by year, Operating Income stood at -$21.3 million in 2020, then increased by 12.62% to -$18.7 million in 2021, then tumbled by 85.32% to -$34.6 million in 2022, then skyrocketed by 35.59% to -$22.3 million in 2023, then crashed by 79.19% to -$39.9 million in 2024.
- Business Quant data shows Operating Income for SLDB at -$39.9 million in Q4 2024, -$35.2 million in Q3 2024, and -$27.8 million in Q2 2024.